Literature DB >> 11005492

Loss of standard type of CD44 expression in invaded area as a good indicator of lymph-node metastasis in colorectal carcinoma.

T Asao1, J Nakamura, Y Shitara, S Tsutsumi, E Mochiki, T Shimura, S Takenoshita, H Kuwano.   

Abstract

PURPOSE: Recent advances have made possible the treatment of small invasive colorectal cancer by means of polypectomy or endoscopic mucosal resection. CD44 expression in cancer cells was identified as an indicator of lymph-node metastasis, which could be evaluated in specimens removed by colonoscopy.
METHODS: The correlation between lymph-node metastasis and the expression of standard-type CD44 in cancer cells was examined immunohistologically using the invaded cancer cells of 61 tissue samples of superficially invasive colorectal cancer. We defined the above as invasive cancer restricted within the colorectal wall. Of the 61 samples, 31 had submucosal invasion and 30 had muscular invasion.
RESULTS: Standard-type CD44 expression in the area of invasion in cases with lymph-node metastasis was remarkably down-regulated. In 43 cases with no lymph-node metastasis, 36 (83.7 percent) of patients had CD44 expression in invaded cells, whereas only two of 18 cases (11.1 percent) with lymph-node metastasis had expression of standard-type CD44 in the same area (P < 0.0001). A total of 69.6 percent (16/23) of patients with loss of standard-type CD44 expression in invaded sites were found to have positive metastasis in the lymph nodes. These results suggest that standard-type CD44 in invasive colon cancer cells could suppress metastasis to the regional lymph nodes.
CONCLUSION: In cases of invasive colorectal cancer, the loss of standard-type CD44 expression in the invaded area is a sensitive marker for metastasis to the lymph nodes. Further investigation with larger patient groups is required to clarify the reliability of loss of standard-type CD44 expression as an indicator for additional surgery after endoscopic resection of submucosal invasive colorectal carcinoma.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11005492     DOI: 10.1007/bf02237430

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  9 in total

Review 1.  CD44 and HCELL: preventing hematogenous metastasis at step 1.

Authors:  Pieter P Jacobs; Robert Sackstein
Journal:  FEBS Lett       Date:  2011-08-05       Impact factor: 4.124

2.  Intrahepatic sarcomatoid cholangiocarcinoma of round cell variant: a case report and immunohistochemical studies.

Authors:  Katsuaki Sato; Hiroshi Murai; Yoshimichi Ueda; Shogo Katsuda
Journal:  Virchows Arch       Date:  2006-10-11       Impact factor: 4.064

3.  Prognostic implications of adhesion molecule expression in colorectal cancer.

Authors:  Kyung-Jin Seo; Maru Kim; Jeana Kim
Journal:  Int J Clin Exp Pathol       Date:  2015-04-01

4.  The Relationships Between Loss of Standard CD44 Expression and Lymph Node, Liver Metastasis in T3 Colorectal Carcinoma.

Authors:  Toshiaki Kunimura; Tomohiko Yoshida; Tomoko Sugiyama; Toshio Morohoshi
Journal:  J Gastrointest Cancer       Date:  2009

5.  Comparison of cyclooxygenase-2 and CD44 mRNA expression in colorectal cancer and its relevance for prognosis.

Authors:  Jung Wook Huh; Hyeong Rok Kim; Jae Hyuk Lee; Young Jin Kim
Journal:  Virchows Arch       Date:  2009-03-10       Impact factor: 4.064

6.  Prognostic Value of E-cadherin-, CD44-, and MSH2-associated Nomograms in Patients With Stage II and III Colorectal Cancer.

Authors:  Jinmiao Qu; Yuming Jiang; Hao Liu; Haijun Deng; Jiang Yu; Xiaolong Qi; Weiting Ge; Guoxin Li
Journal:  Transl Oncol       Date:  2017-01-23       Impact factor: 4.243

7.  Overexpression of CD44v8-10 in Colon Polyps-A Possible Key to Early Diagnosis.

Authors:  Milan Dastych; Frantisek Hubatka; Pavlina Turanek-Knotigova; Josef Masek; Radek Kroupa; Milan Raška; Jaroslav Turanek; Lubomir Prochazka
Journal:  Pathol Oncol Res       Date:  2021-03-30       Impact factor: 3.201

8.  Characteristics of CD44 alternative splice pattern in the course of human colorectal adenocarcinoma progression.

Authors:  Balázs Bánky; Lívia Rásó-Barnett; Tamás Barbai; József Tímár; Péter Becságh; Erzsébet Rásó
Journal:  Mol Cancer       Date:  2012-11-14       Impact factor: 27.401

9.  Selective targeting of human colon cancer stem-like cells by the mTOR inhibitor Torin-1.

Authors:  Maria Giovanna Francipane; Eric Lagasse
Journal:  Oncotarget       Date:  2013-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.